CXCL8 and neoplasm: IL-8/CXCL8, produced by tumor cells, fibroblasts, and myeloid cells, drives neutrophil chemotaxis, angiogenesis, and EMT, correlating with aggressive disease and resistance to targeted and immune therapies [50].